Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Fulvestrant + Compound Gossypol Acetate in Post-CDK4/6 Breast Cancer
NCT06133088Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and gossypol acetate in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
dalpiciclibgossypol acetate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06133088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133088.